

Vantage™ Report


Patient Information	Provisional Diagnosis	Specimen	Provider Information
Name: Jane Doe DOB: 01/01/1990 Sex Assigned at Birth: Female MRN: 11xx22xx33	Diagnosis: Central Nervous System Neoplasm ICD10: C71.9	Type: CSF Collected Date: 05/14/2026 Received Date: 05/15/2026 Specimen ID: Van-Neg-CNS	Ordering Provider: Provider Test Institution: Belay Diagnostics

RESULT SUMMARY

NEGATIVE - Methylation of the *MGMT* promoter was NOT detected.

ACTIONABILITY SUMMARY

Therapies with Resistance/Decreased Response	
Therapy	Setting
temozolomide	Patients with glioblastoma that is not <i>MGMT</i> promoter methylated derive less benefit from treatment with TMZ compared to those whose tumors are methylated (PMID: 15758010).



Honey V Reddi, Ph.D., FACMG, Laboratory Director

TEST DETAILS

Methods and Limitations

The Vantage™ *MGMT* Promoter Methylation Assay utilizes a quantitative PCR (qPCR) followed by high-resolution melt analysis (HRM) using the EpiMelt *MGMT* kit (MethylDetect) after enzymatic conversion (NEBNext Enzymatic Methyl-seq, New England Biolabs) on a portion of the library generated in the Summit™ workflow. Methylated and unmethylated melting temperature peaks are evaluated using the LightCycler® 480 Software v.1.5.1 (Roche LifeScience). Qualitative results are reported as "Negative - Unmethylated", "Positive - Methylated", or "Indeterminate – Results were equivocal". Specimens with results above the validated 25% methylated control are interpreted as "Positive". Specimens with results between unmethylated and methylated control are interpreted as "Indeterminate".

Disclaimers

This test was developed, and its performance characteristics determined by Belay Diagnostics Laboratory (CLIA# 14D2302605), which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). This test may be used for clinical purposes. However, the results of this test do not establish a diagnosis and should not be used alone for diagnosis or patient care decisions or otherwise replace the judgment of a treating physician and must always be interpreted in the context of all relevant clinical and pathological data.

Actionability References

NCCN: National Comprehensive Cancer Network® (NCCN®). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

For Test Purposes Only